Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNOE1M)

• Drug Name: LLY-507 Drug Info
• Synonyms: LLY-507; 1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126
• Cross-matching ID:
  PubChem CID: 91623361
  ChEBI ID: CHEMBL3414623
  TTD Drug ID: D0X3RK

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.40	0.00e+0	19/20 (95%)	MSMO1;SQLE;DHCR24;...
Terpenoid backbone biosynthesis	2.30	0.00e+0	18/22 (81.82%)	HMGCS1;ACAT2;IDI1;...
Complement and coagulation cascades	2.05	0.00e+0	76/85 (89.41%)	C7;TFPI;FGG;...
Steroid hormone biosynthesis	1.94	6.63e-3	43/61 (70.49%)	HSD17B7;AKR1C2;AKR1C3;...
Synthesis and degradation of ketone bodies	1.84	2.65e-2	9/10 (90%)	HMGCS1;ACAT2
Renin-angiotensin system	-1.72	2.37e-2	20/23 (86.96%)	THOP1;PRCP;PREP;...
Viral protein interaction with cytokine and cytokine re...	-1.74	2.15e-2	84/100 (84%)	TNFRSF14;CCL18;CX3CL1;...
Human T-cell leukemia virus 1 infection	-1.75	2.14e-2	197/219 (89.95%)	NFATC3;JAK1;CALR;...
Intestinal immune network for IgA production	-1.75	2.41e-2	38/48 (79.17%)	CCL25;HLA-DQB1;PIGR;...
Viral myocarditis	-1.81	1.62e-2	53/60 (88.33%)	HLA-F;HLA-A;HLA-C;...
Staphylococcus aureus infection	-1.82	1.89e-2	72/95 (75.79%)	HLA-DRA;DEFB4A;C1QA;...
Type I diabetes mellitus	-2.23	0.00e+0	38/43 (88.37%)	IL2;ICA1;HLA-DPA1;...
Graft-versus-host disease	-2.25	0.00e+0	32/42 (76.19%)	HLA-DQB1;KIR2DL3;KIR2DL1;...
Autoimmune thyroid disease	-2.25	0.00e+0	46/53 (86.79%)	IL2;HLA-DPA1;HLA-F;...
Asthma	-2.30	0.00e+0	25/31 (80.65%)	HLA-DRA;HLA-DMB;HLA-DQA1;...
Allograft rejection	-2.48	0.00e+0	32/38 (84.21%)	IL2;HLA-DPA1;HLA-F;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	1.11uM - 10uM	24H	Hide ▲

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	1.11uM - 10uM	24H	Hide ▲